This FREE presentation was recorded during the 2020 Virtual Mental Health Care Conference and is Sponsored by Alkermes. Presented by: Andrew Angelino, MD
Schizophrenia is overrepresented in the criminal justice system, particularly in correctional facilities, with prevalence estimated at 2% to 6.5% in state prison inmates vs. 1.1% in the U.S. adult population. Atypical long-acting injectable therapies should be considered as a treatment option for individuals with schizophrenia during incarceration and as they transition to community care settings. This program will review treatment options, especially use of targeted antipsychotic therapy, to reduce exacerbation of illness and recidivism.
Outline current treatment strategies for patients with schizophrenia
Discuss the future directions in schizophrenia treatment and the symptoms targeted
Explore the impact of targeted pharmacotherapy on recidivism and integration into community treatment
This Free Webinar:
Includes access to the webinar recording and CE credit - 1.0 hours for ACCME, ADA, ANCC, APA and CCHP. If you would like a copy of the presentation and info on how to claim CE credit, please send an email to email@example.com.